🔗 Share this article

While the US undertakes unprecedented adjustments to its vaccine guidelines, an unexpected name has surfaced in a surprising turn: Høeg, an American of Danish descent sports physician and public health researcher who first made her name by questioning coronavirus shots during the global health crisis and has concentrated on potential fatalities after Covid immunization in her short position at the FDA.

Planned Changes to Childhood Vaccine Schedule

Agency leaders planned to announce sweeping changes to the childhood vaccine schedule recently, bringing the US with Denmark’s national calendar, it is understood – a significant shift that would place the US out of step with many the world with little proof for improved outcomes. The planned update has been pushed back until the new year.

Rather than Vinay Prasad, Dr. Høeg is set to present at the gathering. She was newly appointed temporary leader of the FDA’s CDER, the fifth individual to lead the division this year.

A New Direction at the Agency

Høeg's temporary position could signify a tighter collaboration between the pharmaceutical and biologics branches as Dr. Høeg and Dr. Prasad solidify control at the regulatory agency – and it points to a increased emphasis upon reevaluating already-approved vaccines at the FDA.

Høeg has frequently advocated for halting certain childhood vaccine recommendations in the US in order to be more similar to Denmark's approach, a country with nationalized medicine and a number of inhabitants about the size of the state of Wisconsin.

To date statements, she has persisted in emphasizing on vaccines – usually the responsibility of Prasad, chief of the FDA’s vaccine center – as opposed to drug regulation.

Concerns Over Expertise

Dr. Høeg has little discernible track record in pharmaceutical research, oversight or leadership, which has been standard for previous leaders of the Center for Biologics Evaluation and Research. She has worked at the FDA as a top consultant to the commissioner and the vaccine center since earlier this year.

“She appears not to have any of the qualifications” for overseeing the pharmaceutical oversight division, remarked Dr. Jonathan Howard. “She lacks experience running a scientific study. She is not versed in managing a sizeable institution. She is not an expert in pharmaceutical oversight.”

Past commissioners of CBER would “grasp legal statutes and the underlying principles of pharmaceutical innovation”, commented Janet Woodcock. “Objectively, she doesn’t have the kind of background that previous people who ran CBER have had.”

The drug center has an enormous workload at the agency, the former commissioner pointed out.

“Many people just focuses on the innovative therapies, but the off-patent medication office approves a multitude of generic medications. There’s a biosimilars division, non-prescription drug unit and other areas, and all of those need to be managed,” Dr. Woodcock said. “The thing you don’t keep your eye on, that is the part that I always told people is going to bite you.”

Furthermore, a substantial leadership element to the job, which manages more than 5,000 personnel. “It is a massive leadership role, if you execute it properly,” she added.

Agency Reaction and Contentious Initiatives

Regarding inquiries about Dr. Høeg's qualifications and whether this assignment indicates more teamwork among FDA leaders on vaccines, a spokesperson stated that the “questions stem from inaccurate presumptions”.

“This background matches the duties of her role,” the spokesperson stated, pointing to the period Dr. Høeg spent advising the FDA commissioner on “drug safety and regulatory science, including computational safety modeling and immunization monitoring”.

As acting director, Høeg takes over the commissioner’s recently launched fast-track approval initiative, a controversial one-day drug-approval program that allegedly concerned her preceding directors. “By what process are these therapies being selected for this expedited pathway? Who makes the decisions?” Howard said. “There is a lot of lack of transparency happening at the agency right now.”

Overall, he stated, “the agency looks to be trending towards less stringent rules of all drugs, except for shots.”

Established Past Work on Vaccines

With immunizations, Høeg has a more established, if concerning, history, critics have noted. She released a analysis using unverified public submissions to assess the incidence of myocarditis following Covid vaccination. She counseled the Florida top health official Joseph Ladapo, who reportedly have changed statistics to imply Covid vaccines are riskier than they are.

Part of her “wish list” for the incoming federal leadership featured altering rules for new vaccines and ending “unnecessary” vaccines, she remarked after the election on a audio program. At the agency, Dr. Høeg has reportedly floated the idea of barring adolescent males from receiving Covid vaccinations.

“She is an thorough dogmatist who begins with her beliefs and tailors the evidence to fit the data in a extremely deceptive, dishonest way,” Dr. Howard said.

Taking Control and a “Push for Payback”

Dr. Høeg joined fellow contrarians, {like|